2022
DOI: 10.1016/s2215-0366(22)00161-4
|View full text |Cite
|
Sign up to set email alerts
|

Association of cannabis potency with mental ill health and addiction: a systematic review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
57
0
5

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 105 publications
(63 citation statements)
references
References 40 publications
1
57
0
5
Order By: Relevance
“…Corroborating previous reports, we observed that patients using cannabis were more likely to present with concomitant substance use disorders related to alcohol, nicotine and drugs including cocaine, intravenous drugs, psychedelics and opioids, which corroborates findings of previous studies. 10 , 11 , 12 , 37 , 38 , 39 …”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Corroborating previous reports, we observed that patients using cannabis were more likely to present with concomitant substance use disorders related to alcohol, nicotine and drugs including cocaine, intravenous drugs, psychedelics and opioids, which corroborates findings of previous studies. 10 , 11 , 12 , 37 , 38 , 39 …”
Section: Discussionmentioning
confidence: 99%
“…There was further a higher prevalence of psychiatric disorders including anxiety and depression in patients consuming cannabis. 10 , 38 , 40 , 41 , 42 As these comorbidities have been associated with increased complications including arrhythmias and sudden cardiac death after anaesthesia, 43 , 44 a history of cannabis use disorder use might serve as an indicator of potentially complicating factors for patients undergoing anaesthesia that in turn contribute to the requirement of higher level healthcare utilisation after surgery.…”
Section: Discussionmentioning
confidence: 99%
“…The concentration of compounds in the cannabis plant can be identified from scientific literature and accredited cannabis testing labs [45]. While not risk-free (and assuming the product is compliant with cannabis contaminant limits and being used by adults as intended), vaporizing cannabis likely poses less health risk than cannabis combustion (i.e., smoking "joints") due to the reduction of toxic compounds caused by thermal degradation at high temperatures [46][47][48][49]. This is important for many cannabis consumers who see vaporization as a harm reduction tool so there may be cases where some toxicological risk (if it is less than smoking cannabis) may be acceptable.…”
Section: Gathering the Data (Hazard Identification)mentioning
confidence: 99%
“…As an adjuvant treatment, CBM is often used in combination with opioids (26) and, for that reason, is often a last pharmacological resort for treating CP. Despite recent reviews mostly focused on CBM in comorbid mental disorders (27), evidence remains inconclusive about the most effective time point to use CBM to treat patients with CP and the most adequate treatment duration. Beyond that, little is known about CBM's efficacy with comorbid mental disorders and other psychosocial determinants.…”
Section: Introductionmentioning
confidence: 99%